




Searching News Database: orphan drug
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 31 Dec 2024
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
HSMN NewsFeed - 20 Jun 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
HSMN NewsFeed - 19 Jun 2024
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
European Commission grants Sobi(R) Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
HSMN NewsFeed - 31 May 2024
SIFI Receives Positive CHMP Opinion for Akantior(R) (polihexanide 0.08%) in Acanthamoeba Keratitis
SIFI Receives Positive CHMP Opinion for Akantior(R) (polihexanide 0.08%) in Acanthamoeba Keratitis
HSMN NewsFeed - 30 May 2024
US FDA Awards Supplemental Orphan Drug Designation to Survaxm to Now Include Treatment of Malignant Glioma
US FDA Awards Supplemental Orphan Drug Designation to Survaxm to Now Include Treatment of Malignant Glioma
HSMN NewsFeed - 14 May 2024
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
HSMN NewsFeed - 15 Dec 2023
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
HSMN NewsFeed - 20 Nov 2023
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 24 Oct 2023
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
HSMN NewsFeed - 19 Jun 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
HSMN NewsFeed - 6 Jan 2023
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
HSMN NewsFeed - 24 Aug 2022
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
HSMN NewsFeed - 20 Jul 2022
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
HSMN NewsFeed - 16 Jun 2021
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
HSMN NewsFeed - 14 Jun 2021
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
HSMN NewsFeed - 11 May 2021
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
HSMN NewsFeed - 5 Apr 2021
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer
HSMN NewsFeed - 30 Mar 2021
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
PTC Therapeutics Announces the European Approval of Evrysdi(TM) for the Treatment of Spinal Muscular Atrophy
HSMN NewsFeed - 17 Mar 2021
Peptilogics Strengthens Leadership Team with Three Strategic Appointments
Peptilogics Strengthens Leadership Team with Three Strategic Appointments
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 11 Jun 2020
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin
HSMN NewsFeed - 19 May 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
HSMN NewsFeed - 24 Apr 2020
Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd(R)
Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd(R)
HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
HSMN NewsFeed - 3 Mar 2020
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases
HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
HSMN NewsFeed - 29 Jan 2020
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
vasopharm Completes Patient Enrollment for Phase III Traumatic Brain Injury Trial (NOSTRA)
HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
HSMN NewsFeed - 19 Nov 2019
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
CNS Pharmaceuticals Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmaceuticals
HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
HSMN NewsFeed - 19 Jul 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
HSMN NewsFeed - 20 Jun 2019
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
HSMN NewsFeed - 29 Jan 2019
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
HSMN NewsFeed - 29 Jan 2019
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
HSMN NewsFeed - 21 Dec 2018
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
HSMN NewsFeed - 3 Dec 2018
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
HSMN NewsFeed - 3 Dec 2018
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
HSMN NewsFeed - 28 Nov 2018
Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.
Generex Biotechnology Expands Medical Device Portfolio With Acquisition of Olaregen Therapeutix Inc.
HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
HSMN NewsFeed - 1 Nov 2018
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
HSMN NewsFeed - 25 Sep 2018
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
HSMN NewsFeed - 17 Sep 2018
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
HSMN NewsFeed - 23 Aug 2018
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
HSMN NewsFeed - 17 Jul 2018
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
HSMN NewsFeed - 13 Jul 2018
Modus Therapeutics Completes a SEK 140 Million Financing led by HealthCap
Modus Therapeutics Completes a SEK 140 Million Financing led by HealthCap
HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
HSMN NewsFeed - 20 Apr 2018
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen
HSMN NewsFeed - 9 Apr 2018
RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome
HSMN NewsFeed - 5 Mar 2018
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation
HSMN NewsFeed - 30 Jan 2018
FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly
FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly
HSMN NewsFeed - 27 Dec 2017
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
HSMN NewsFeed - 26 Dec 2017
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
HSMN NewsFeed - 13 Dec 2017
Kangen Pharmaceuticals Co., Ltd. Announces Acquisition Of KC Specialty Therapeutics
Kangen Pharmaceuticals Co., Ltd. Announces Acquisition Of KC Specialty Therapeutics
HSMN NewsFeed - 27 Nov 2017
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
Stealth BioTherapeutics Granted Fast Track Designation for the Treatment of Barth Syndrome
HSMN NewsFeed - 16 Nov 2017
FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
FDA Approves New Treatment to Prevent Bleeding in Certain Patients with Hemophilia A
HSMN NewsFeed - 31 Oct 2017
Mitosol(R)'s Orphan Drug Designation is Expanded for All Glaucoma Surgery
Mitosol(R)'s Orphan Drug Designation is Expanded for All Glaucoma Surgery
HSMN NewsFeed - 6 Oct 2017
Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
HSMN NewsFeed - 5 Sep 2017
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
HSMN NewsFeed - 31 Aug 2017
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
HSMN NewsFeed - 15 Aug 2017
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 6 Jul 2017
Biohaven's BHV-5000 Receives Orphan Drug Designation from the FDA in Rett Syndrome
Biohaven's BHV-5000 Receives Orphan Drug Designation from the FDA in Rett Syndrome
HSMN NewsFeed - 15 Jun 2017
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
HSMN NewsFeed - 27 Apr 2017
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
HSMN NewsFeed - 25 Apr 2017
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
HSMN NewsFeed - 17 Apr 2017
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
HSMN NewsFeed - 28 Mar 2017
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
HSMN NewsFeed - 15 Feb 2017
Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer
HSMN NewsFeed - 3 Jan 2017
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
HSMN NewsFeed - 28 Dec 2016
Concordia International Corp. Announces Leadership Transition at International Segment
Concordia International Corp. Announces Leadership Transition at International Segment
HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
HSMN NewsFeed - 29 Nov 2016
Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
Albireo Expands Team, Appoints Martha J. Carter as Chief Regulatory Officer
HSMN NewsFeed - 29 Nov 2016
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Conditional Approval from the European Commission to Treat Multiple Myeloma
HSMN NewsFeed - 14 Nov 2016
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer
HSMN NewsFeed - 20 Sep 2016
Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera(R)
Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera(R)
HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 4 Aug 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
HSMN NewsFeed - 28 Jul 2016
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes
HSMN NewsFeed - 20 Jul 2016
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations
HSMN NewsFeed - 29 Jun 2016
Biostage Files for FDA Orphan Drug Designation for Cellspan(TM) Esophageal Implant
Biostage Files for FDA Orphan Drug Designation for Cellspan(TM) Esophageal Implant
HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 7 Jun 2016
Sanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary
Sanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary
HSMN NewsFeed - 17 May 2016
Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 15 Mar 2016
Heart Metabolics Announces Multiple Senior Appointments To Management Team
Heart Metabolics Announces Multiple Senior Appointments To Management Team
HSMN NewsFeed - 4 Mar 2016
Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business
Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business
HSMN NewsFeed - 26 Feb 2016
Catalyst Pharmaceuticals Appoints Brian Elsbernd as Senior Vice President of Legal and Compliance
Catalyst Pharmaceuticals Appoints Brian Elsbernd as Senior Vice President of Legal and Compliance
HSMN NewsFeed - 17 Feb 2016
Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
HSMN NewsFeed - 29 Jan 2016
RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial
RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial
HSMN NewsFeed - 23 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
HSMN NewsFeed - 21 Jan 2016
vasopharm Announces EUR 20 Million Fundraising to Progress Treatment for Traumatic Brain Injury
vasopharm Announces EUR 20 Million Fundraising to Progress Treatment for Traumatic Brain Injury
HSMN NewsFeed - 19 Jan 2016
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
HSMN NewsFeed - 12 Jan 2016
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 19 Nov 2015
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
HSMN NewsFeed - 19 Oct 2015
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
AVAX Technologies, Inc. Announces the Appointment of Chief Executive Officer
HSMN NewsFeed - 1 Oct 2015
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono
HSMN NewsFeed - 15 Sep 2015
Makindus Bolsters Management Team with Appointment of Michael Celano as Chief Financial Officer
Makindus Bolsters Management Team with Appointment of Michael Celano as Chief Financial Officer
HSMN NewsFeed - 31 Aug 2015
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis
HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
HSMN NewsFeed - 16 Jul 2015
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
HSMN NewsFeed - 27 May 2015
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
HSMN NewsFeed - 8 Apr 2015
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
HSMN NewsFeed - 18 Feb 2015
aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris(TM) in FSHD
aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris(TM) in FSHD
HSMN NewsFeed - 5 Jan 2015
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
HSMN NewsFeed - 4 Sep 2014
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
HSMN NewsFeed - 3 Sep 2014
Eisai Sells U.S. Rights to Zonegran(R) (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
Eisai Sells U.S. Rights to Zonegran(R) (zonisamide) Capsules to Concordia Pharmaceuticals Inc.
HSMN NewsFeed - 5 Aug 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
HSMN NewsFeed - 23 Jul 2014
FDA Approves Eagle Pharmaceuticals’ Ryanodex(R) for the Treatment of Malignant Hyperthermia
FDA Approves Eagle Pharmaceuticals’ Ryanodex(R) for the Treatment of Malignant Hyperthermia
HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
HSMN NewsFeed - 9 Jun 2014
FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Leigh Syndrome
FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Leigh Syndrome
Additional items found! 500

Members Archive contains
500 additional stories matching:
orphan drug
(Password required)
orphan drug
(Password required)